Skip to main content

Table 4 Parameters

From: The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Parameter Presentation Test
PVPi (days 1, 2, 4, and 7) Mean ± SD Linear mixed model
Oxygenation index (days 1, 2, 4, 7, 10, and 28) Mean ± SD Linear mixed model
PaO2/FiO2 ratio (days 1, 2, 4, 7, 10, and 28) Mean ± SD Linear mixed model
Airway driving pressure (days 1, 2, 4, 7, 10, and 28) Mean ± SD Linear mixed model
Compliance (days 1, 2, 4, 7, 10, and 28) Mean ± SD Linear mixed model
Mechanical power (days 1, 2, 4, 7, 10, and 28) Mean ± SD Linear mixed model
SOFA score (days 1, 2, 4, 7, 10, and 28) Mean ± SD Linear mixed model
Number of ventilator-free days (days 1 to 28) Mean ± SD T-test
Duration of mechanical ventilation (days) (days 1 to 28) Mean ± SD T-test
Length of ICU stay (days) (days 1 to 28) Mean ± SD T-test
Hospital length of stay (days) (days 1 to 28) Mean ± SD T-test
28-day mortality Number (%) Cox prop. Hazards
Plasma biomarkers (days 1, 2, 4, 7, and 10) Median ± IQR MWU / Linear mixed model
Blood cell counts (days 1, 2, 4, 7, and 10)   
RBC Mean ± SD Linear mixed model
WBC Mean ± SD Linear mixed model
Thrombocytes Mean ± SD Linear mixed model
Kidney function (days 1, 2, 4, 7, and 10)   
Creatinine Mean ± SD Linear mixed model
eGFR Mean ± SD Linear mixed model
Liver enzymes (days 1, 2, 4, 7, and 10)   
ALT Mean ± SD Linear mixed model
AST Mean ± SD Linear mixed model
Bilirubin Mean ± SD Linear mixed model
γ-glutamyl transferase Mean ± SD Linear mixed model
Alkaline phosphatase Mean ± SD Linear mixed model
NT-proBNP (days 1, 2, 4, 7, and 10) Median ± IQR Linear mixed model
SAEs / AE Number (%) Descriptive
ECG (ΔQTc time day 1 versus day 4) Mean ± SD T-test